Evaluation of Betatrophin hormone in Patients with type 2 diabetes

Abstract

Background: Diabetes mellitus Type 2  (DMT2) is a chronic metabolic disorder characterized by high blood glucose level due to insulin resistance, which in turn reduces the secretion of insulin hormone relatively   . Such metabolic disorders often result in failure of pancreatic beta cells function and their lack of differentiation and thus lack of insulin secretion . Betatrophin hormone (B.H.) is a protein hormone consisting of 198 amino acids . B.H. is considered one of the newly discovered hormones, as many studies have confirmed  and demonstrated the relationship between obesity and diabetes and B.H. because the B.H. has several important metabolic roles .                                                                                   

Materials and methods: The current  study involved selection 25 individuals of  healthy  group (first group) and individuals of newly DMT2 group (second group), age of all individuals > 40 of both genders. For all individuals were measured Ins.H. , c-peptide , RBS HbA1c and B.H. levels in serum and whole blood . The statistical analysis method was t-test to explain the clinical significant value when compare between 2 groups .                        

Results: This study results  reveals the significant elevation of the  c-peptide , RBS , HbA1c and B.H. level in second group compared with first group . In study , the t-test used by mean ± standard deviation (SD) to compare between groups .                                                       

Conclusion: The results of the current study summarize that the level of B.H.  increases at the onset of DMT2 , and this increase is an attempt by the body to enhance the mass of pancreatic beta  cells to regulate and enhance the secretion of insulin .